Publication & Citation Trends
Publications
0 total
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196 OA
Cited by 4
Semantic Scholar
High prevalence of sexually transmitted infections, homelessness and drug use among street-based sex workers in London: Results from a pilot intervention of mobile outreach testing and treatment
Cited by 3
Semantic Scholar
900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study) OA
Cited by 5
Semantic Scholar
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection OA
Cited by 86
Semantic Scholar
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study OA
Cited by 210
Semantic Scholar
Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies OA
Cited by 33
Semantic Scholar
Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) OA
Cited by 32
Semantic Scholar
Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. OA
Cited by 14
Semantic Scholar
Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies OA
Cited by 4
Semantic Scholar
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cited by 305
Semantic Scholar
Research Topics
HIV/AIDS drug development and treatment
(35)
HIV Research and Treatment
(30)
HIV/AIDS Research and Interventions
(16)
HIV-related health complications and treatments
(13)
Hepatitis C virus research
(6)
Affiliations
University of North Carolina at Chapel Hill
Research Triangle Park Foundation
The University of Texas Health Science Center at San Antonio
ViiV Healthcare (Spain)
Burroughs Wellcome Fund